[go: up one dir, main page]

EP3264898A1 - Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles - Google Patents

Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles

Info

Publication number
EP3264898A1
EP3264898A1 EP16715881.5A EP16715881A EP3264898A1 EP 3264898 A1 EP3264898 A1 EP 3264898A1 EP 16715881 A EP16715881 A EP 16715881A EP 3264898 A1 EP3264898 A1 EP 3264898A1
Authority
EP
European Patent Office
Prior art keywords
composition
bees
composition according
microorganisms
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16715881.5A
Other languages
German (de)
English (en)
Inventor
Stefano Trovo´
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3264898A1 publication Critical patent/EP3264898A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Definitions

  • the present invention relates to compositions and methods for the biological control of the well-being of hive bees, and in particular relates to the treatment and prevention of the most widespread bee diseases due to microbiological etiology, such as those caused by bacteria and fungi infesting the colony of bees and the hive.
  • the composition and the method according to the present invention are useful for the maintenance of the bees good health and for the prophylaxis and the treatment of bacterial and fungal infections, and in particular of Nosema disease and of pathologies due to infestations of other concomitant agents.
  • Maintaining the good condition of the beekeeping sector is obviously important not only for the production of honey and other bee products, but also for the more wide action on pollination of agricultural crops and entomophilous plant species.
  • an increase in bee mortality has been repeatedly reported and several health problems have affected the beekeeping sector in different countries worldwide. This raised great concern for significant environmental and economic consequences. It is quite evident, therefore, the need to counteract this beekeeping impoverishment through targeted measures, considering that the main causes are pathologies affecting the hive and the not always correct use of agro-drugs. Therefore, it is necessary to focus the activity on new strategies, able to fight bee diseases with low environmental impact substances.
  • microorganisms or particular groups of microorganisms, able to exert a beneficial effect to increase the well-being and the resistance of bees against various pathogens, to increase the bee immunological defences has been introduced.
  • the microbial associations have been shown to be very effective therapeutic agents that have found application in beekeeping.
  • the patent application JP19980047329 describes a method for the treatment of health problems due to bee mites and a method for improving the bees immune system by supplementing bee feed with a mixture of Bacillus subtilis, Lactobacillus lactis and Lactobacillus bifidus and bifidobacteria and sugars.
  • the patent application DE 4215534 describes the use of a composition, applied in a method of treatment of varroa, nosema and in general to diseases affecting bees, comprising the administration of a mixture comprising Lactobacillus helveticus and Lactobacillus acidophilus, lactose and inorganic salts.
  • the patent application RM 2012A000635 describes a composition comprising the association of microorganisms of the species: Lactobacillus paracasei ssp., Bifidobacterium bifidum, Lactobacillus acidophilus r Lactococcus lactis r Bifidobacterium animalis , Lactobacillus thermophilus , Bacillus clausii , in 5% sucrose solution.
  • the composition has been shown to induce a positive effect on the bees health and to be particularly useful for the treatment of serious infections such as those determined by CBPV virus infection and/or by Nosema ceranae infections. Kaznowski et al .
  • probiotic supplementation has investigated the effects of probiotic supplementation on the content of intestinal microflora and chemical composition of worker bees ⁇ Apis mellifera) , in particular the authors have tested two probiotic mixtures used as supplements to pollens substitute in feeding honey bees; the advantageous effect deriving from probiotic supplementation has been evaluated in terms of bee survival, higher dry mass and crude fat level in comparison to bees fed with pollen substitute only from 14 and 2 days treatment.
  • One of the two tested probiotic mixture contains the following bacterial species: Pediococcus acidilactici (10%), Lactobacillus acididophilus (35%), Enterococcus faecium (5%) and Bifidobacterium bifidum (50%), the second one contains Lactobacillus acididophilus (37,5%), Lactobacillus delbrueckii subspecies bulgaricus (25%), and Bifidobacterium bifidum (50%) .
  • the international patent application WO 2014/170233 discloses a mixture of Lactobacillus buchneri , Lactobacillus plantarum and Lactococcus lacti used in a method for improving milk-quality in milk producing animals, more specifically the document teaches feeding cows with fermented silage produced by inoculating perennial ryegrass with Lactobacillus plantarum CH6072 (DSM16568), Lactococcus lactis 0224 (DSM11037), L . buchneri Lbl819 (DSM22501), and optionally also Lactococcus lactis (NCIMB 30117) .
  • the US patent US 6,403,084 Bl disclose a mixture of Lactobacillus buchneri and Lactobacillus plantarum for the use as silage inoculants and the method of treating animal feed or silage with the silage inoculants. More specifically the document teaches to combine specific bacterial species in the proper ratio to provide both an adequate fermentation of silage or animal feed as well as an enhanced aerobic stability upon exposure of the silage or feed to air.
  • the silage inoculant is a combination of at least one viable strain of the homofermentive lactic acid bacteria Lactobacillus plantarum and at least one viable strain of the heterofermentive lactic acid bacteria Lactobacillus buchneri or Lactobacillus brevis.
  • the silage inoculant will comprise at least 2 to 10 strains of homofermenter and/or heterofermenter .
  • Exemplary strains of L. plantarum include at least one of LP286, LP287, LP329, LP346, LP347, or functional mutants thereof.
  • Exemplary strains of L . buchneri include LN1391, LN4637, LN4750, or functional mutants thereof.
  • the silage inoculant optionally comprises at least one viable strain of Enterococcus faecium, such as but not limited to, strains EF301, EF202, or functional mutants thereof.
  • the number of viable homofermentive bacteria and heterofermentive bacteria in the inoculant are present in a ratio of from about 1:5 to about 1:15. In some embodiments the ratio is about: 1:6 to 1:14, 1:7 to 1:13, 1:8 to 1:12, 1:9 to 1:11, or 1:10.
  • bee diseases are divided into brood diseases and diseases of the adult, including also fungal diseases; there are also some diseases, eg. the acariosis, damaging both bee broods and adult bees.
  • Nosema disease affects adult bees, it is caused by unicellular fungi belonging to the class of Microsporidia, Nosematidi Family, Gender Nosema.
  • Two different species of Nosema affect bees: Nosema apis and Nosema ceranae, responsible for two different pathology forms.
  • Nosema apis is responsible for the "classic" gastro ⁇ enteric disease, whereas Nosema ceranae has been reported more recently in bees as the causative agent of a disease form characterized by slow depopulation of the colony until its death. Both N. apis and N. ceranae appear at the optical microscope in the form of spores, morphologically indistinguishable between the two species: a differential diagnosis can be performed only through genome analysis of the spores. Nosema apis lives and spreads in the epithelial cells of the digestive tract of adult bees. It affects the larval stages.
  • apis in the bee colony the first symptoms appear, such as diarrhea, the young nurses become unable to secrete the royal jelly, while gatherer bees reduce their activity, until it stops completely. A slow depopulation of the colony occurs, the work decreases. Bees are no longer able to fly. Finally, the hive is smeared by diarrhea, and on the bottom of the hive, dead bees with the swollen and soft abdomen appear. The establishment of such severe conditions favours the simultaneous onset of other diseases, such as amoebiase or viruses, exacerbates the feature of Nosema disease. In temperate zones the disease begins to be manifest usually in late winter, the overt symptoms are seen in April- May.
  • the aim of the present invention is to provide a composition enabling a treatment against hive diseases induced by bacterial and fungal infections, against fungal diseases affecting the brood, such as stone brood ⁇ Aspergillus flavus) and chalk brood (Ascosphera apis) , against diseases induced by Nosema apis and Nosema cerana, and bacterial diseases such as American foul brood and European foul brood that very often affect apiaries.
  • composition according to the invention determines on bee families a stimulating and reinforcing effect, and reduce sensitivity to other concomitant pathogens.
  • composition according to the invention comprises the association of specific bacterial strains hence promoting the establishment in the hive of a corrective and protective microflora whose metabolic activity produces substances that induce a positive effect on the conditions of the bee colony.
  • composition comprising the association of microorganisms according to the invention enables to limit the reduction in brood that naturally and physiologically occurs in the hive at the end of summer season.
  • composition according to the invention comprises the biological association of viable microorganisms of the species Lactobacillus buchneri and viable microorganisms of at least one specie selected from the group of: Pediococcus pentosaceus, Lactococcus lactis, and Lactobacillus plantarum, and prebiotic agents .
  • Figure 1 shows the diagram illustrating the percentage of change in the number of adult bees in beehives subjected to treatment with the composition of microorganisms according to the invention obtained by the estimation of sixths;
  • Figure 2 shows the diagram illustrating the percentage of change in the number of broods, without specifying whether these are operculated or not, in the hives subjected to treatment with the composition of microorganisms according to the invention obtained by estimating sixths;
  • Figure 3 shows the diagram illustrating the percentage of change in the compactness of the brood in the hives subjected to treatment with the composition of microorganisms according to the invention obtained by the estimation of sixths;
  • Figure 4 shows the diagram illustrating the number of dead bees found in the hives seven days after the first administration of the composition of microorganisms according to the invention
  • Figure 5 shows the diagram illustrating the average weight of the supers placed above the hive for each experimental group
  • Figure 6 shows a diagram illustrating the change in the Nosema spp . infection level expressed as a function of the number of spores per bee, before and after treatment with the composition of microorganisms according to the invention
  • Figure 7 shows the diagram illustrating the percentage change in the entity of the infection from Nosema spp. expressed as a function of the number of spores per bee, before and after treatment with the composition of microorganisms according to the invention.
  • lactobacilli are essential to maintain a state of optimal health in humans and in animal species
  • physiological and therapeutic properties of lactobacilli vary depending on the specific features of each strain. It has also been shown that there are considerable differences between different strains of L. acidophilus, and that the same strain, grown in different environments and conditions, shows different properties (Bhatia, V. 1991. Growth optimization of L. acidophilus in whey. MS Thesis, Univ. of Kansas, Lincoln) .
  • the invention provides a biological composition comprising a specific association of viable microorganisms, prebiotic agents, sugars, salts and minerals, one or more excipients and carriers.
  • the specific association of viable microorganisms comprises microorganisms of the species Lactobacillus buchneri and microorganisms of at least one species selected from the group of: Pediococcus pentosaceus, Lactobacillus plantarum and Lactococcus lactis.
  • the microorganism association comprises bacteria of the species Lactobacillus buchneri and Lactococcus lactis.
  • the microorganism association comprises bacteria of the species Lactobacillus buchneri and Pediococcus pentosaceus .
  • the microorganisms association comprises bacteria of the species Lactobacillus buchneri,. Pediococcus pentosaceus and Lactococcus lactis.
  • Another particularly preferred embodiment of the invention provides in the microorganism association the presence of probiotic bacteria of the species Lactobacillus buchneri, Lactobacillus plantarum and Pediococcus pentosaceus .
  • the bacterial strains of the association in the composition of the present invention have been selected for their metabolic properties and for their probiotic activity, which have been found highly effective against the onset of Nosema disease and related diseases thereof.
  • the use of the combination of the mentioned bacterial strains is designed to strengthen the bees immune system, resulting in a preventive and curative treatment of infections .
  • the bacterial strains of the specific association according to the invention are obtained from official collections such as DSM, CCM, NCIMB collections.
  • composition comprising the association of viable microorganisms of the species Lactobacillus buchneri and viable microorganism of at least one species selected from the group of: Pediococcus pentosaceus, Lactobacillus plantarum and Lactococcus lactis, further comprises: sugars, salts and minerals, prebiotic agents, at least one or more carriers and excipients.
  • the composition comprises inulin and/or fructooligosaccharides (FOS), silica, maltodextrin, levulose, sucrose, sodium chloride.
  • FOS fructooligosaccharides
  • composition is obtained by mixing the lyophilized preparation of the bacterial strains of the biological association of microorganisms, together with the other provided components.
  • the microorganisms are at a concentration ranging between l-2xl0 9 and l-2xl0 13 cfu/gram, preferably microorganisms are at a concentration of 1-2X10 11 cfu/gram, and in particular L. buchneri is present in amount of at least 2xl0 10 cfu/gram; the amount of the microorganisms of the other bacterial strains in the composition is varying between 1x10 and 2x10 .
  • bacteria of the strain Pediococcus pentosaceus are present in the composition at a concentration of at least lxlO 7 cfu/gram
  • bacteria of the strains Lactobacillus plantarum and Lactococcus lactis are present in the composition at a concentration of at least 2xl0 10 cfu/gram.
  • composition according to the invention may be in either liquid or dry form, however in a preferred embodiments it is in dry form wherein the viable bacteria are lyophilized. Lyophilisation is performedaccording to standard techniques known to the skilled persons.
  • composition according to the invention is in solid form, such as capsules, tablets, granules, powder.
  • the composition according to the invention is in the form of powders to be dissolved in water before use, i.e. before administration to the hive. It is thus presented as a product packaged in sachets containing 10 g of the composition containing the optimum amount for the complete treatment of 20 hives.
  • a further object of the present invention is the use of the composition comprising the described association of microorganisms, prebiotic agents, salts and minerals, and one or more excipients and carriers, in the treatment and prevention of infection caused by certain pathogens of bees, in particular in the treatment of the infection caused by unicellular fungi like Nosema.
  • composition according to the invention involves the administration of the composition to bees, larvae, beehive and other components related to the hive.
  • a feature particularly advantageous from the use of the composition according to the invention is the fact that it can be used in the hive even in the presence of supers.
  • composition according to the invention comprises the following steps:
  • composition according to the invention in 2 litres of water directly into a sealable container, close the container and mix thoroughly;
  • composition solution by spraying, by syringe, by inoculation into the feeder and in any other method known to the skilled persons, adapted to bring the solution in contact with the bees, .
  • the dissolved solution can be used within 7 days if stored tightly closed and in a cool, dry place.
  • composition according to the invention by spraying, about 10 ml of solution prepared as above described, are sprayed either on each frame hive in the brood nest without extracting the frames, or directly on honeycombs, after opening the roof and the crown board.
  • composition according to the invention in the case of dispensing the composition according to the invention by a syringe, about 10 ml of solution prepared as above described are spread over each frame hive in the brood nest without extracting the frames, after opening the roof and the crown board.
  • composition according to the invention for the treatment of bacterial and fungal diseases affecting the hive, the Nosema disease, and for the strengthening of the bee family and for increasing the compactness of brood requires to perform 3-4 treatments:
  • composition according to the invention can also be used in winter as feeding administrated by feeder, possibly also together with a syrup.
  • composition according to the invention has a high potential in protecting adult and larvae bees by multiple mechanisms of action.
  • the treatment resulted in a high protection in the bees colony against the external stress and a considerable improvement of the well-being of the treated bees and a considerable containment of Nosema spp . infections.
  • the present invention provides an alternative technical solution for the treatment of bacterial and fungal bee diseases; in particular the composition according to the invention and the relative method of use has resulted to be effective in the treatment of Nosema disease and of other concomitant pathologies establishing with the disease, compared to those already present in the state of the art, such as the composition for the treatment of varroa, Nosema disease, and in general other diseases affecting bees, that combine different types of lactobacilli in the presence of sugar.
  • composition according to the invention has a high potential in protecting adult bees and larvae by multiple mechanisms of action.
  • the treatment resulted in the colony a high protection against the external stress and a considerable improvement of the well- being of the colony of bees treated and the considerable reduction of the presence of the pathogen responsible for Nosema disease.
  • the positive effect deriving from the use of the composition was determined according to the strength of families of bees, through the evaluation of parameters indicative of the good condition of the bee colony and strength of bee colonies, by the estimate of the sixth, the discovery of the diarrhea phenomena, by the assessment of the brood compactness, bee mortality, amount of honey produced and evaluation of infection by Nosema spp.
  • composition against bee disorders established by microbial pathogens and more generally on the health of the bees was investigated by in vivo experiments carried out from July 2014 to September 2014 in an apiary located in the territory of Lazio region, Italy.
  • composition according to the invention comprising a probiotic mixture constituted by the mixture of lyophilized microorganisms of the species Lactobacillus buchneri , Pediococcus pentosaceus and Lactococcus lactis with total concentration of 2x1 ⁇ 11 cfu/g, prebiotic agents, sugars, salts and minerals, one or more excipients and carriers, as reported in table 1 of this description.
  • the effectiveness of the treatment with said composition was evaluated by the following parameters and in accordance with the timetable indicated:
  • score 2 corresponds to a number of broods in the range 75 - 85%;
  • score 4 corresponds to a number of broods in the range 90 - 95%
  • time 2 one month after the end of the last treatment ; • time 3: every time the probiotic composition is administered .
  • Group PRO MIN which received the lowest recommended dose of composition comprising viable bacteria in amount equal to lxlO 6 cfu per ml of composition solution, corresponding to 10 g of the lyophilized composition according to the invention dissolved in 1 1 of water.
  • Group PRO 10 which received a dose of probiotic composition comprising viable bacteria in amount equal to 3xl0 7 cfu per ml of composition solution, corresponding to 30x10 g of the lyophilized composition according to the invention dissolved in 1 1 of water.
  • Honeycomb covered with bees of each experimental group were sprayed with 10 ml of the relative solution comprising the association of viable bacteria of the strains Lactobacillus buchneri , Pediococcus pentosaceus and Lactococcus lactis, or of the control solution with no bacteria.
  • the honeycombs have received an administration every 14 days.
  • the strength of a hive is evaluated through the number of adult worker, the extension of the brood and the amount of stocks.
  • the amount of brood and stocks are quantified by counting the cells.
  • honeycombs calibrated photographs or defined surface area with known number of bees and/or cells.
  • Such surface usually are elliptic or rectangular areas corresponding to 1/6 of honeycomb surface (Accorti M. Numerical evaluation of adult Apis mellifera: variations and changes to the method of the sixth. Beekeeping No. 01 - Ed. Inst. Experimental Agricultural Zoology Florence, Rome 1985) .
  • Figure 5 shows that the amount of honey produced in the experimental groups is lower compared to the control group according to the average weight of the supers .
  • Half amount of distilled water added to collect the spores spread on the walls of the bag was removed and stored in a test tube, the remaining sample was homogenized for 2 minutes (Stomacher - Seward Ltd) .
  • the homogenate was poured in a 15 ml polystyrene conical bottom Falcon test tube; using previously stored distilled water spores spread on the walls of the bag were harvested and joined to the sample in the Falcon tube.
  • the tube was centrifuged for 6 minutes at 800 rpm. The supernatant was discarded and distilled water was added until reaching 3 ml volume wherein the spores were resuspended.
  • the centrifugation was further repeated 3 times so as to create a suspension of spores of Nosema spp . 85% pure (Fries I. et al . 2013. Standard methods for Nosema research. Journal of Apicultural Research 52 (1) .
  • composition administrated according to the described method provides a greater compactness of the brood and has shown to limit the Nosema disease .
  • the results provide insights about the dosage of the composition allowing to obtain the best performance in term of well-being of bees.
  • the most effective dosage was found in the experimental PRO MAX group (3xl0 6 cfu/ml), whereas the most effective dose to treat Nosema spp . infections resulted to be that received by the experimental PRO lOx group (3xl0 7 cfu/ml) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition comprenant l'association de micro-organismes viables de l'espèce Lactobacillus buchneri et de micro-organismes viables d'au moins une espèce choisie dans le groupe constitué par : Pediococcus pentosaceus, Lactococcus lactis et Lactobacillus plantarum, et des agents prébiotiques destinés à être utilisés dans la lutte biologique pour le bien-être des abeilles, dans la prophylaxie et le traitement des maladies des abeilles provoquées par le champignon de l'espèce Nosema et destinés à être utilisés dans la réduction de la diminution physiologique de couvains se produisant à la fin de l'été dans la ruche.
EP16715881.5A 2015-02-26 2016-02-24 Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles Withdrawn EP3264898A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM20150087 2015-02-26
PCT/IB2016/051016 WO2016135655A1 (fr) 2015-02-26 2016-02-24 Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles

Publications (1)

Publication Number Publication Date
EP3264898A1 true EP3264898A1 (fr) 2018-01-10

Family

ID=52781208

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16715881.5A Withdrawn EP3264898A1 (fr) 2015-02-26 2016-02-24 Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles

Country Status (2)

Country Link
EP (1) EP3264898A1 (fr)
WO (1) WO2016135655A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051344A1 (fr) * 2016-09-14 2018-03-22 Grace Breeding Ltd. Compositions comprenant des bactéries non pathogènes et procédés de protection d'hôtes végétaux et animaux contre des maladies fongiques, bactériennes et virales
WO2020191508A1 (fr) * 2019-03-27 2020-10-01 Universidad San Sebastián Biostimulant et bio protecteur, procédé de fabrication et utilisations correspondantes en agriculture
CN110295199B (zh) * 2019-07-24 2021-12-03 天津科技大学 一种抑制黄曲霉的复合发酵物及其制备方法和应用
PL246744B1 (pl) * 2022-04-22 2025-03-03 Univ Marii Curie Sklodowskiej W Lublinie Sposób otrzymywania preparatu białkowego i preparat białkowy do zastosowania w zwalczaniu nosemozy u pszczoły miodnej

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215534C1 (en) 1992-05-12 1993-06-17 Merckle Gmbh, 7900 Ulm, De Solns. used to treat bee diseases - contg. lactic acid, aminoacid(s) and iron, manganese and phosphate salts
US6403084B1 (en) 2000-11-03 2002-06-11 Pioneer Hi-Bred International, Inc. Mixed cultures for improved fermentation and aerobic stability of silage
NZ586384A (en) 2004-09-01 2012-03-30 Pioneer Hi Bred Int Ferulate esterase producing Lactobacillus buchneri strain LN4888 and methods of using same in silage production
PL2142635T3 (pl) * 2007-05-03 2019-01-31 Tobias Olofsson Nowe szczepy bakterii wyizolowane z przewodu wytwarzania miodu u pszczół miodnych
ITRM20120635A1 (it) 2012-12-12 2014-06-13 Stefano Trovo' "composizione utile per il controllo biologico delle malattie delle api"
EP3001792A2 (fr) 2013-04-18 2016-04-06 Chr. Hansen A/S Méthode d'amélioration de la qualité du lait chez des animaux producteurs de lait

Also Published As

Publication number Publication date
WO2016135655A1 (fr) 2016-09-01

Similar Documents

Publication Publication Date Title
Antúnez et al. Efficacy of natural propolis extract in the control of American Foulbrood
Audisio et al. Lactobacillus johnsonii CRL1647, isolated from Apis mellifera L. bee-gut, exhibited a beneficial effect on honeybee colonies
Smriti et al. Prospects of probiotics in beekeeping: a review for sustainable approach to boost honeybee health
Abdi et al. The promise of probiotics in honeybee health and disease management
EP3264898A1 (fr) Composition biologique pour lutter contre les pathologies et les infections microbiologiques des abeilles
KR20240130711A (ko) 불안 장애의 치료 및/또는 예방에 있어서 포스트바이오틱스의 용도
ES2215412T3 (es) Tratamiento contra la enfermedad de las larvas de las abejas.
CN114828880B (zh) 蜜蜂疫苗和使用方法
Hansen et al. Control of American foulbrood by the shaking method
Coffey Parasites of the Honeybee
WO2014097338A1 (fr) Composition utile pour la lutte biologique contre des maladies des abeilles
Milián et al. Use of microbial additives in apiculture
MacLean et al. Gruiformes (cranes, limpkins, rails, gallinules, coots, bustards)
Russenova et al. DIAGNOSTICS AND CONTROL
US20210138006A1 (en) Systems, Methods, and Compositions for Treating or Preventing Bacterial Infection and for Reducing or Preventing Bacterial Overpopulation
CN115895933A (zh) 一种乳杆菌firm5 M27及其应用
Mahmoud et al. Field application of honeybees’ endogenous lactic acid bacteria for the control of American foulbrood disease
Vilarem et al. Lactic acid impairs Varroa destructor grip skill: fitness costs and effects on behaviour under artificial conditions
KR20230156739A (ko) 무척추동물의 세균 질병에 대한 백신 방법 및 조성물
Munawar et al. Controlling American Foulbrood in honeybees by shook swarm method
WO2021018841A1 (fr) Procédés et compositions pour réduire les nuisibles ou lutter contre ceux-ci
Ostermann Interactions of varroa, Varroa destructor Anderson and Trueman, with chalkbrood, Ascosphaera apis (Maassen ex Claussen) Olive & Spiltoir, and nosema, Nosema apis Zander, in honey bee, Apis mellifera L., colonies treated with formic acid, and the influence of hive and ambient conditions on formic acid concentration in the hive
Ianiro Antibiotic and Probiotic activity of Lactic Acid Bacteria isolated from Honeybee gut and Beebread
Murray Effects of used brood comb and propolis on honey bees (Apis mellifera L.) and their associated bacterium, Melissococcus plutonius
Plavša et al. Evaluation of oxytetracycline in the prevention of American foulbrood in bee colonies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180619